BESPONSA can cause liver problems that can be severe, life-threatening, or fatal, including a condition called veno-occlusive disease (VOD). This condition can occur during treatment with BESPONSA or following subsequent treatment with a stem cell transplant. This condition was more common in patients who had elevated liver tests or who received dual alkylating agents in preparation for their stem cell transplant. Patients may be at a higher risk of VOD if they: . # The IV Co-Pay Program will pay the co-pay and any deductible obligations for the Product up to the annual assistance limit of $25,000 per calendar year per patient. Medicare/Government Insured If you have Medicare/Medicare Part D, Medicaid, or another government insurance plan, Pfizer Oncology Together can help identify financial support resources.. ¶For patients to be eligible for the IV Co-Pay Program, they must have commercial insurance that covers BESPONSA™ (inotuzumab ozogamicin) or MYLOTARG™ (gemtuzumab ozogamicin) (each referred to as “Product”) and they cannot be enrolled in a state or federally funded insurance program..